Skip to main content
NIH funding notice PAR-20-232

Enabling Technologies to Accelerate Development of Oral Biodevices (R21 Clinical Trial Not Allowed)

Closed on May 7, 2023.

Posted
June 16, 2020
Close date
May 7, 2023
Activity codes
Not stated on the notice page
Institutes taking part
Not stated on the notice page

Read the notice on Grants.gov · NIH Guide page

The notices it replaced

Its page was not saved, so the notices it replaced are not known.

Who won it before

2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $528,084 in first-year total cost, median $264,042.

Most frequent study sections

  1. Bioengineering, Technology and Surgical Sciences Study Section[BTSS]1
  2. Special Emphasis Panel[ZRG1 BST-U (80)]1

Most frequent institutions

  1. OREGON STATE UNIVERSITY1
  2. UNIVERSITY OF VIRGINIA1
Competing awards under PAR-20-232 and the notices it replaced
FYProjectPIsInstitutionFirst-year costStudy section
2023Novel Implementation of Microporous Annealed Particle HydroGel for Next-generation Posterior Pharyngeal Wall Augmentation1R21DE033155-01DANIERO, JAMES J.MASON, KAZLINUNIVERSITY OF VIRGINIA, VA$323,000BTSS
2022Development of an intraoral device for therapeutic drug monitoring of anti-epileptic drugs1R21DE031101-01A1FU, ELAINJOHNSTON, MATTHEW LRAMSEY, STEPHEN A.OREGON STATE UNIVERSITY, OR$205,084ZRG1

Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.

ScienceDex for faculty

Your academic CV and NIH biosketch

Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.